GEN Exclusives

More »

GEN News Highlights

More »
Oct 25, 2010

BD Diagnostics and Lonza to Market MicroCompass Molecular Assays for BD Max System

  • Becton Dickinson’s BD Diagnostics and Lonza inked an exclusive licensing and collaboration deal to commercialize the latter’s microCompass™ molecular assays on BD Max™ system. The deal gives Lonza an exclusive worldwide license to co-market the BD Max system with the complete microCompass product line in selected fields within the pharmaceuticals and personal care products markets.

    The firms are also collaborating on the development and optimization of what they claim will be rapid, automated, and easy-to-use microbial testing solutions that allow "load and walk away" operation.

    The BD Max system for molecular testing uses microfluidics and molecular biology to fully automate nucleic acid extraction and recovery, PCR setup, amplification, and detection. The companies claim Lonza’s microCompass assays will facilitate rapid detection for total bioburden load, sterility testing, Mycoplasma, and a range of specific organisms.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?